[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 739,854
  • Shares Outstanding, K 82,573
  • Annual Sales, $ 0 K
  • Annual Income, $ -247,300 K
  • EBIT $ -326 M
  • EBITDA $ -331 M
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.48

Options Overview Details

View History
  • Implied Volatility 113.15% (-5.36%)
  • Historical Volatility 217.37%
  • IV Percentile 9%
  • IV Rank 4.47%
  • IV High 792.98% on 07/28/25
  • IV Low 81.32% on 12/17/25
  • Expected Move (DTE 2) 0.60 (6.87%)
  • Put/Call Vol Ratio 0.39
  • Today's Volume 930
  • Volume Avg (30-Day) 6,224
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 122,836
  • Open Int (30-Day) 109,851
  • Expected Range 8.18 to 9.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.73
  • Number of Estimates 5
  • High Estimate $-0.68
  • Low Estimate $-0.77
  • Prior Year $-0.82
  • Growth Rate Est. (year over year) +10.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.47 +96.42%
on 05/27/26
10.86 -19.15%
on 06/04/26
+3.56 (+68.20%)
since 05/15/26
3-Month
1.50 +485.33%
on 04/13/26
10.86 -19.15%
on 06/04/26
+1.42 (+19.29%)
since 03/16/26
52-Week
1.50 +485.33%
on 04/13/26
13.24 -33.69%
on 07/21/25
-1.05 (-10.68%)
since 06/16/25

Most Recent Stories

More News
REPL's Cash Runway Narrative May Finally Collide With Clinical Reality Tomorrow

Barchart Research What to Expect from REPL Earnings REPL Generated June 10, 2026 Current Price $8.47 EPS Estimate $$-0.73 Consensus Rating Hold Average Move 3.60% REPL's Cash Runway Narrative May Finally...

REPL : 8.78 (-2.01%)
Replimune's Path to Profitability Grows More Uncertain With Each Delayed Milestone

Barchart Research What to Expect from REPL Earnings REPL Generated June 3, 2026 Current Price $9.98 EPS Estimate $$-0.73 Consensus Rating Hold Average Move 3.60% Replimune's Path to Profitability Grows...

REPL : 8.78 (-2.01%)
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented...

REPL : 8.78 (-2.01%)
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented...

REPL : 8.78 (-2.01%)
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 8.78 (-2.01%)
Replimune's Clinical Pipeline Impresses but the Burn Rate Story Keeps Getting Harder to Defend

Barchart Research What to Expect from REPL Earnings REPL Generated May 27, 2026 Current Price $4.70 EPS Estimate $$-0.73 Consensus Rating Hold Average Move 3.60% Replimune's Clinical Pipeline Impresses...

REPL : 8.78 (-2.01%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).  Such investors are advised...

REPL : 8.78 (-2.01%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised...

REPL : 8.78 (-2.01%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised...

REPL : 8.78 (-2.01%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).  Such investors are...

REPL : 8.78 (-2.01%)

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United...

See More

Key Turning Points

3rd Resistance Point 9.29
2nd Resistance Point 9.12
1st Resistance Point 8.95
Last Price 8.78
1st Support Level 8.62
2nd Support Level 8.45
3rd Support Level 8.28

See More

52-Week High 13.24
Last Price 8.78
Fibonacci 61.8% 8.76
Fibonacci 50% 7.37
Fibonacci 38.2% 5.98
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.